Press Releases from DelveInsight (693 total)
Candidiasis Clinical Trials Analysis 2025: Oral Agents, Next-Generation Echinoca …
DelveInsight's "Candidiasis - Clinical Trials Analysis, 2025" examines an active clinical landscape addressing both mucosal (vulvovaginal) and invasive candidiasis. Unmet needs for safe, oral, and…
Necrotizing Enterocolitis Clinical Trials Analysis 2025: Probiotics, HMOs, and R …
DelveInsight's "Necrotizing Enterocolitis (NEC) - Clinical Trials Analysis, 2025" highlights an evolving pipeline aimed at reducing NEC incidence and severity in preterm infants. With NEC…
Brain Hemorrhage Clinical Trials Analysis 2025: Hemostasis, Neuroprotection, and …
DelveInsight's "Brain Hemorrhage - Clinical Trials Analysis, 2025" surveys an active acute-care landscape focused on reducing hematoma expansion, limiting secondary injury, and improving functional recovery…
Cachexia Clinical Trials Analysis 2025: Metabolic Modulators, Anabolic Therapies …
DelveInsight's "Cachexia - Clinical Trials Analysis, 2025" examines a diverse development landscape targeting the complex metabolic, inflammatory, and neurohormonal drivers of cancer- and disease-related wasting.…
Cystitis Clinical Trials Analysis 2025: Novel Antimicrobials, Non-antibiotic Pre …
DelveInsight's "Cystitis - Clinical Trials Analysis, 2025" reviews an active pipeline addressing both uncomplicated and complicated urinary tract infections (UTIs)/cystitis, with emphasis on recurrent cystitis…
Nasopharyngeal Cancer Clinical Trials Analysis 2025: Immunotherapies, Targeted A …
DelveInsight's "Nasopharyngeal Cancer (NPC) - Clinical Trials Analysis, 2025" explores an evolving pipeline focused on improving outcomes for patients with advanced or recurrent disease. Despite…
Hereditary Angioedema Clinical Trials Analysis 2025: Novel Therapeutics, Prophyl …
DelveInsight's "Hereditary Angioedema (HAE) - Clinical Trials Analysis, 2025" reviews a rapidly evolving clinical pipeline designed to prevent and manage acute HAE attacks. Despite available…
Cutaneous Lupus Erythematosus Clinical Trials Analysis 2025: Targeted Immunomodu …
DelveInsight's "Cutaneous Lupus Erythematosus (CLE) - Clinical Trials Analysis, 2025" highlights a dynamic pipeline addressing persistent gaps in treatment for patients with lupus-specific skin manifestations.…
Febrile Neutropenia Clinical Trials Analysis 2025: Antimicrobial Stewardship, No …
DelveInsight's "Febrile Neutropenia - Clinical Trials Analysis, 2025" reviews an evolving pipeline focused on reducing infection-related complications in cancer patients undergoing chemotherapy. Despite advances in…
Vasculitis Clinical Trials Analysis 2025: Targeted Immunotherapies, Complement I …
DelveInsight's "Vasculitis - Clinical Trials Analysis, 2025" highlights a dynamic pipeline aimed at improving remission durability and minimizing steroid dependence in this group of rare,…
Advanced Gastric Carcinoma Clinical Trials Analysis 2025: Targeted Agents, Immun …
DelveInsight's "Advanced Gastric Carcinoma (AGC) - Clinical Trials Analysis, 2025" reviews a rapidly evolving clinical pipeline focused on enhancing overall survival, response durability, and tolerability…
Advanced Urothelial Carcinoma Clinical Trials Analysis 2025: Targeted Therapies, …
DelveInsight's "Advanced Urothelial Carcinoma (aUC) - Clinical Trials Analysis, 2025" examines a dynamic pipeline focused on improving survival, response rates, and tolerability for patients with…
Post-Polycythemia Vera Myelofibrosis Clinical Trials Analysis 2025: Novel JAK In …
DelveInsight's "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Clinical Trials Analysis, 2025" highlights an evolving pipeline designed to tackle the limitations of current therapies and improve long-term…
Immunologic Deficiency Syndrome Clinical Trials Analysis 2025: Gene Therapies, N …
DelveInsight's "Immunologic Deficiency Syndrome - Clinical Trials Analysis, 2025" reviews the rapidly evolving clinical landscape for primary and selected secondary immunodeficiency disorders, a heterogeneous group…
Vestibular Schwannoma Clinical Trials Analysis 2025: Hearing-Preservation Strate …
DelveInsight's "Vestibular Schwannoma - Clinical Trials Analysis, 2025" examines the evolving clinical-trial landscape for vestibular schwannoma (VS). This typically benign cranial nerve tumor can cause…
Diabetic Foot Ulcers Pipeline Insight 2025: 25+ Regenerative, Antimicrobial, and …
DelveInsight's "Diabetic Foot Ulcers - Pipeline Insight, 2025" survey examines more than 25 therapies in development that address diabetic foot ulcers (DFUs), a leading cause…
Attention Deficit Hyperactivity Disorder Clinical Trials Analysis 2025: Novel Me …
DelveInsight's "Attention Deficit Hyperactivity Disorder (ADHD) - Clinical Trials Analysis, 2025" reviews an evolving pipeline focused on enhancing symptom control, reducing side effects, and improving…
Motor Neuron Disease Pipeline Insight 2025: Gene-Targeted Therapies, Neuroprotec …
DelveInsight's "Motor Neuron Disease - Pipeline Insight, 2025" highlights 200+ therapies in development for ALS and related motor neuron disorders. Despite supportive care being the…
Herpes Labialis Clinical Pipeline Insight 2025: Antivirals, Vaccines, and Long-A …
DelveInsight's "Herpes Labialis - Clinical Pipeline Insight, 2025" reviews more than 6+ therapies in development for herpes labialis (cold sores), a recurrent infection most commonly…
Microbiome Disease Pipeline Insight 2025: 180+ Pipeline Drugs, Live Biotherapeut …
DelveInsight's "Microbiome Disease - Pipeline Insight, 2025" covers over 180+ therapies in development targeting microbiome-associated diseases across diverse therapeutic areas, including gastrointestinal, metabolic, dermatological, neurological,…
Renal Cancer Clinical Trials Analysis 2025: Next-Generation Targeted Therapies a …
DelveInsight's "Renal Cancer - Clinical Trials Analysis, 2025" explores the rapidly evolving therapeutic landscape for renal cell carcinoma (RCC), the most common form of kidney…
Polymyositis Clinical Trial Analysis 2025: How Emerging Therapies Are Shaping th …
DelveInsight's "Polymyositis - Pipeline Insight, 2025" examines the evolving therapeutic landscape for polymyositis, a rare autoimmune inflammatory myopathy characterized by progressive muscle weakness and systemic…
Ulcerative Colitis Clinical Trials Analysis 2025: Advancing Biologics, Small Mol …
DelveInsight's "Ulcerative Colitis - Clinical Trials Analysis, 2025" reviews the expanding landscape of therapies in development for ulcerative colitis (UC), a chronic inflammatory bowel disease…
Amyloid Light-Chain Amyloidosis Clinical Trials Analysis 2025: Emerging Therapie …
DelveInsight's "Amyloid Light-Chain (AL) Amyloidosis - Clinical Trials Analysis, 2025" examines the evolving therapeutic landscape for Amyloid Light-Chain Amyloidosis, a rare and life-threatening disorder characterized…
Psoriatic Arthritis Clinical Trials Analysis 2025: Expanding Biologics, Small Mo …
DelveInsight's "Psoriatic Arthritis - Clinical Trials Analysis, 2025" highlights the dynamic evolution of the therapeutic landscape for psoriatic arthritis (PsA), a chronic immune-mediated inflammatory arthritis…
Ischemic Stroke Clinical Trials 2025: Tenecteplase FDA Approval, Thrombectomy Up …
DelveInsight's "Ischemic Stroke - Clinical Trials, 2025" captures a rapidly evolving landscape in which improvements in acute reperfusion (thrombolysis and endovascular thrombectomy), adjunctive neuroprotection, and…
Attention Deficit Hyperactivity Disorder Clinical Trials 2025: 22+ Pipeline Ther …
DelveInsight's "Attention Deficit Hyperactivity Disorder - Clinical Trials, 2025" reviews over 22 therapies in development for ADHD, a highly prevalent neurodevelopmental disorder affecting both children…
Chronic Heart Failure Clinical Trials 2025: 25+ Pipeline Therapies, SGLT2 Inhibi …
DelveInsight's "Chronic Heart Failure - Clinical Trials, 2025" highlights 25+ therapies in development for CHF, a progressive condition marked by high morbidity and mortality. Beyond…
Beta-Thalassemia Clinical Trials 2025: 22+ Pipeline Therapies, Gene Editing, and …
DelveInsight's "Beta-Thalassemia - Clinical Trials, 2025" reviews over 22 therapies in development for beta-thalassemia, a rare inherited blood disorder characterized by impaired hemoglobin production and…
Atopic Dermatitis Clinical Trials 2025: Incyte Announces Additional FDA Approval …
DelveInsight's "Atopic Dermatitis - Clinical Trials, 2025" reviews 90+ therapies currently in development for atopic dermatitis, a chronic inflammatory skin condition that imposes a high…
Moderate to Severe Inflammatory Acne Vulgaris Clinical Trials, 2025: 15+ Pipelin …
DelveInsight's "Moderate to Severe Inflammatory Acne Vulgaris - Clinical Trials, 2025" reviews 15+ therapies in development for acne vulgaris, a chronic dermatologic disease marked by…
Parkinson's Disease Pipeline Insight 2025: 100+ Pipeline Drugs, Gene, Cell, and …
DelveInsight's "Parkinson's Disease - Pipeline Insight, 2025" surveys a robust and fast-moving pipeline of 100+ investigational therapies spanning small molecules, biologics, gene, and cell therapies.…
Mitochondrial Myopathies Pipeline Insight 2025: Advancing Novel Therapeutics for …
DelveInsight's "Mitochondrial Myopathies - Pipeline Insight, 2025" explores the evolving landscape of therapies in development for mitochondrial myopathies, a group of rare, progressive neuromuscular disorders…
Metastatic Melanoma Clinical Trials 2025: 75+ Pipeline Drugs, Targeted Therapies …
DelveInsight's "Metastatic Melanoma - Clinical Trials, 2025" reviews 75+ therapies currently in development for metastatic melanoma, one of the most aggressive forms of skin cancer…
Multiple System Atrophy Pipeline Insight 2025: 22+ Pipeline Drugs, Disease-Modif …
DelveInsight's "Multiple System Atrophy (MSA) - Pipeline Insight, 2025" reviews a growing portfolio of 22+ therapies in development for MSA, a rare, rapidly progressive neurodegenerative…
Hepatocellular Carcinoma Pipeline Insight 2025: 95+ Pipeline Drugs, Targeted Age …
DelveInsight's "Hepatocellular Carcinoma - Pipeline Insight, 2025" explores over 95+ therapies in development for hepatocellular carcinoma (HCC), the most common form of primary liver cancer…
Insulin Resistance Pipeline Insight 2025: Pipeline Drugs, Metabolic Pathway Modu …
DelveInsight's "Insulin Resistance - Pipeline Insight, 2025" explores over 10+ therapies in development for insulin resistance, a metabolic condition strongly linked to type 2 diabetes,…
Uveal Melanoma Pipeline Insight 2025: 30+ Pipeline Drugs, Targeted Therapies, an …
DelveInsight's "Uveal Melanoma - Pipeline Insight, 2025" explores over 30+ therapies in development for uveal melanoma, a rare and aggressive intraocular malignancy with high metastatic…
Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shap …
DelveInsight's "Peptic Ulcers - Pipeline Insight, 2025" examines over 8+ therapies in development for peptic ulcer disease, a condition affecting millions worldwide with peptic ulcer…
Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trial …
DelveInsight's "Vaso-Occlusive Crisis (VOC) Associated With Sickle Cell Disease - Pipeline Insight, 2025" provides an in-depth analysis of emerging therapies targeting vaso-occlusive crisis (VOC), a…
Pemphigus Vulgaris Clinical Trials 2025: Emerging Therapies, Key Players, and Tr …
DelveInsight's "Pemphigus Vulgaris - Pipeline Insight, 2025" provides a comprehensive overview of the evolving treatment landscape for pemphigus vulgaris, a rare, chronic, and potentially life-threatening…
Peripheral Arterial Clinical Trial Analysis 2025: 22+ Emerging Therapies, Novel …
DelveInsight's "Peripheral Arterial Disease - Pipeline Insight, 2025" explores over 22+ therapies in development for peripheral arterial disease (PAD), a chronic and progressive condition caused…
Ovarian Cancer Clinical Trial Analysis 2025: 200+ Pipeline Drugs, PARP Inhibitor …
DelveInsight's "Ovarian Cancer - Pipeline Insight, 2025" reviews over 200+ therapies in development for ovarian cancer, one of the most challenging gynecologic malignancies with high…
HER2-Positive Breast Cancer Pipeline Insight 2025: 55+ Pipeline Drugs, Targeted …
DelveInsight's "HER2-Positive Breast Cancer - Pipeline Insight, 2025" highlights over 55+ therapies in development for HER2-positive breast cancer, one of the most aggressive breast cancer…
Focal Segmental Glomerulosclerosis Pipeline Insight 2025: 18+ Emerging Therapies …
DelveInsight's "Focal Segmental Glomerulosclerosis - Pipeline Insight, 2025" reviews more than 18+ therapies in development for focal segmental glomerulosclerosis (FSGS), a rare and severe form…
Non-Muscle Invasive Bladder Cancer Pipeline Insight 2025: 22+ Emerging Therapies …
DelveInsight's "Non-Muscle Invasive Bladder Cancer - Pipeline Insight, 2025" highlights more than 22+ therapies in development for non-muscle invasive bladder cancer (NMIBC). In this prevalent…
Leishmaniasis Pipeline Insight 2025: Emerging Drugs, Novel Antiparasitic Approac …
DelveInsight's "Leishmaniasis - Pipeline Insight, 2025" highlights over 3+ drugs in development for leishmaniasis, a neglected tropical disease caused by Leishmania parasites and transmitted through…
Liposarcoma Pipeline Insight 2025: 15+ Pipeline Drugs, Targeted Therapies, and I …
DelveInsight's "Liposarcoma - Pipeline Insight, 2025" explores over 15+ therapies in development for liposarcoma, a rare and heterogeneous soft tissue sarcoma subtype. Despite surgery and…
Type 1 Diabetes Pipeline Insight 2025: 100+ Pipeline Drugs, Cell Therapies, and …
DelveInsight's "Type 1 Diabetes - Pipeline Insight, 2025" explores the fast-evolving pipeline of more than 100+ therapies in development for type 1 diabetes (T1D), an…
Atrial Fibrillation Pipeline Insight 2025: 15+ Pipeline Drugs, Gene Therapies, a …
DelveInsight's "Atrial Fibrillation - Pipeline Insight, 2025" examines more than 15+ therapies in development for atrial fibrillation (AF), the most common sustained cardiac arrhythmia associated…
